INTRODUCTION

COGNIZA contains Cerebroprotein hydrolysate which belongs to the group of medicine called neurotrophic agents. It is used to treat traumatic brain injury, ischemic stroke, vascular dementia and Alzheimer's disease. Cerebroprotein hydrolysate is a unique drug with small neurological peptides produced by standardized enzymatic breakdown of lipid-free porcine brain proteins. It contains numerous neurotrophic factors which enhances neurogenesis, neuronal survival, neuromodulatory action, neuronal repair and has neuroimmunotrophic actions. It reduces excitotoxic damage and offers protection against ischemic and neurotoxic lesions.

Take this medicine as directed by your physician. Your doctor will decide the correct dose and duration for you depending upon your condition. Do not take this medicine, if you have any pre-existing epileptic conditions such as status epilepticus or grand mal seizure, as this medicine may increase the frequency of seizure attacks. Before taking this medicine, inform your doctor if you have any renal insufficiency or renal dysfunction. COGNIZA should be used in pregnant or breastfeeding women only if it is clearly necessary due to lack of data on human study. Discuss the risks and benefits with your doctor. The most common side effects of taking this medicine are nausea, vomiting, indigestion, tremor or flu-like symptoms. Contact your doctor if any of these symptom bothers you. Avoid concomitant use of this medicine with antidepressants, as they may increase the risk of side effects.

USES OF COGNIZA

• Treats traumatic brain injury
• Treats vascular dementia
• Treats ischemic stroke
• Treats Alzheimer's disease

HOW COGNIZA WORKS

Cerebroprotein hydrolysate is composed of numerous small biological peptides with neurotrophic activity, that enhances neurogenesis, neuronal survival and promotes trophic action on neuronal cells. It reduces excitotoxic damage and offers protection against ischemic and neurotoxic lesions.

DIRECTIONS FOR USE

Take COGNIZA as directed by your physician. Swallow the medicine as whole with a sip of water. Do not crush or chew the medicine. Your doctor will decide the correct dose and duration for you depending upon your condition. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.

SIDE EFFECTS OF COGNIZA

HOW TO MANAGE SIDE EFFECTS

Nausea or vomiting:

Try taking this medicine with, or just after meals. Stick to simple meals. Do not eat rich or spicy food.

Constipation:

Eat fibre rich foods like fresh fruit, vegetables and cereals. Drink plenty of water. Exercise more regularly.

Diarrhea:

Drink lots of fluids, such as water or juice, to avoid dehydration. Do not take any medicines without speaking to a doctor.

Headache:

Rest and drink plenty of fluids. Do not drink too much alcohol.

Loss of appetite:

Eat when you are hungry. Try to eat smaller meals more often frequently. Snack only when you're hungry. Always try to have a nutritious snack that is high in calories and protein, such as dried fruit and nuts.

WARNING & PRECAUTIONS

INTERACTIONS

Talk to your doctor, if you are taking,

• medicines used to treat depression (e.g. fluoxetine, sertraline, fluvoxamine)

SYNOPSIS

MORE INFORMATION

Store below 20-25°C and keep out of reach of children.

FAQs ABOUT COGNIZA

What are the uses of COGNIZA?

It is used to treat traumatic brain injury, ischemic stroke, vascular dementia and Alzheimer's disease. It enhances neurogenesis, neuronal survival, neuromodulatory action, neuronal repair and has neuroimmunotrophic actions.

Can COGNIZA cause flu?

Yes. It may sometimes cause flu-like symptoms (cold, cough, fever) in some individuals. It is usually temporary and vanishes with time. However, if this symptom bothers you, contact your doctor for advice.

Can COGNIZA be taken during pregnancy?

It should be used in pregnant women only if it is clearly necessary. Discuss the risks and benefits with your doctor.

REFERENCES

1. Perry B. Molinoff. Neurotransmission and the Central Nervous System. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 375.

2. Perry B. Molinoff. Neurotransmission and the Central Nervous System. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 381.

3. Mosam Phirke, Avinash Desousa, Nilesh Shah, Sushma Sonavane, Anup Bharati. The use of cerebroprotein hydrolysate in dementia: A case series of 25 cases seen in a tertiary general hospital. Journal of geriatric mental health. 2014. [Accessed 3rd December 2020] https://www.jgmh.org/article.asp?issn=2348-9995;year=2014;volume=1;issue=2;spage=106;epage=109;aulast=Phirke

4. Zehui Liu, Wanyan Wang, Tingyu Huang, Cunfang Wang, Ying Huang, Yong Tang and Jin Huang and Hemachandra Reddy. CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease. NCBI; PMC US National Library of Medicine, National Institute of Health. September 2019. [Accessed 3rd December 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756745/

5. Ciplamed. CEREBROCIP Injection (Cerebroprotein hydrolysate). Ciplamed.com. [Revised on August 2017] [Accessed 3rd December 2020] https://www.ciplamed.com/content/cerebrocip-injection

6. II Douglas James Phillips. Cerebroprotein hydrolysate for treating brain injuries and neurodegenerative conditions effecting the brain. Patents.google.com. April 2012. [Accessed 3rd December 2020] https://patents.google.com/patent/US20120083450A1/en

USEFUL DIAGNOSTIC TESTS

• Activated Partial Thromboplastin Time
• Complete Blood Count
• Prothrombin Time